Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Champions Biotechnology sets up UK subsidiary
Champions Biotechnology, a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary,
Champions Biotechnology, a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a UK subsidiary,
Engage is expected to enroll 1,200 patients with abdominal aortic aneurysms at up to 80 medical centers across six continents. Patients who meet the single-arm study’s inclusion criteria
According to Wright Medical, the Prophecy program will enable surgeons to utilize basic CT or MRI scan technology to plan precise implant placement and alignment, before they enter
Tibotec, a division of Janssen-Ortho, has announced that Health Canada has approved Prezista for use in treatment-naive adults, dosed once daily in combination with other antiretroviral agents. The
Interest revenues amounted to $37,047 in the first quarter of 2009, compared with $259,434 in the first quarter of 2008. The change in interest revenue resulted from the
Mr Leach also resigned as a director of Integrated BioPharma, and his director and officer positions with its subsidiaries. Mr Leach will continue to be employed by the
Intercell, a biotechnology company, has initiated a Phase I clinical trial with the company’s vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae. This Phase
Mithridion, a biopharmaceutical company, has announced encouraging results from a Phase I pharmacokinetic and clinical study of MCD-386, its lead drug candidate for Alzheimer’s disease. The Phase I
Elan, a neuroscience-based biotechnology company, and Wyeth have announced that the companies will discontinue the highest of three dosing regimens, 2mg/kg, in the two ongoing Phase III studies
The company has said that the new product is suitable for: students who are about to graduate; people who are between jobs; part-time, temporary or seasonal employees, recent